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Abstract 
Purpose: To evaluate the therapeutic potential of new bi-heterocycles containing a 1,3-thiazole and 
1,3,4-oxadiazole in the skeleton against Alzheimer's disease and diabetes, supported by in-silico study. 
Methods: The synthesis was initiated by the reaction of 4-methyl-1,3-thiazol-2-amine (1) with 
bromoacetyl bromide (2) in aqueous basic medium to obtain an electrophile,2-bromo-N-(4-methyl-1,3-
thiazol-2-yl)acetamide (3). In parallel reactions, a series of carboxylic acids, 4a-r, were converted 
through a sequence of three steps, into respective 1,3,4-oxadiazole heterocyclic cores, 7a-r, to utilize as 
nucleophiles. Finally, the designed molecules, 8a-r, were synthesized by coupling 7a-r individually with 
3 in an aprotic polar solvent. The structures of these bi-heterocycles were elucidated by infrared (IR), 
electron ionization-mass spectrometry (EI-MS), proton nuclear magnetic resonance (1H-NMR) and 
carbon nuclear magnetic resonance (13C-NMR). To evaluate their enzyme inhibitory potential, 8a-r were 
screened against acetylcholinesterase (AChE), but brine shrimp lethality bioassay. 
Results: The most active compound against AChE was 8l with half-maximal inhibitory concentration 
(IC50) of 17.25 ± 0.07 µM. Against BChE, the highest inhibitory effect was shown by 8k (56.23 ± 0.09 
µM). Compound 8f (161.26 ± 0.23μM) was recognized as a fairly good inhibitor of urease. In view of its 
inhibition of α-glucosidase, 8o (57.35 ± 0.17μM) was considered a potential therapeutic agent. 
Conclusion: The results indicate that some of the synthesized products with low toxicity exhibit  notable 
enzyme inhibitory activity against selected enzymes compared with the reference drug, and therefore, 
are of potential therapeutic interest  
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The chemistry and biological study of 
heterocyclic compounds has been an interesting 
field for a long time in medicinal chemistry. 
Thiazoles play a crucial role in the activity of 
biological compounds. For example, the thiazole 
ring is a component of vitamin B1 (thiamine), an 
important coenzyme of carboxylases. This 
heterocycle is also present in penicillins, which 
serve as antibiotics [1]. In addition, high 
antioxidant, anti-inflammatory and inhibitory 
effects of thiazoles have been observed in vitro 
in their action against parasites (Plasmodium and 
Trypanosoma) and fungi (Candida albicans) [2]. 
Similarly, 1,3,4-oxadiazoles have demonstrated a 
range of bioactivities [3-5].Molecules bearing this 
moiety are known to possess anti-parasitic, 
hypoglycemic, anti-inflammatory, antifungal and 
antibacterial activities [6-8]. 
 
Cholinesterases, acetylcholinesterase (AChE) 
and butyrylcholinesterase (BChE), belong to the 
class of serine hydrolases. Acetylcholine activity 
is terminated at cholinergic synapses by these 
enzymes, and these enzymes are also found at 
neuromuscular junctions and cholinergic brain 
synapses [9]. It is known that BChE is associated 
with Alzheimer's plaque in notably elevated 
quantities. The inhibitors of these enzymes may 
have future prospects as curative agents for 
Alzheimer’s disease [10]. α-Glucosidase 
inhibitors (AGIs) such as acarbose and miglitol 
have been approved for clinical use in controlling 
the digestion of complex carbohydrates in  the 
gut and may be used in the treatment of patients 
with type 2 diabetes or impaired glucose 
tolerance [11]. Urease is involved in different 
pathogenic processes such as pyelonephritis, 
peptic ulceration, hepatic encephalopathy, 
urolithiasis and urinary catheter encrustation [12]. 
Molecular docking analysis approximates ligands 
regarding their orientation and conformation at 
the binding site of target proteins. The precise 
prediction of activity and structural modeling can 
be achieved by docking studies. Furthermore, it 
elucidates the active site of proteins and 
interactions by inhibitors [13]. 
 
New drugs are continually being synthesized, 
aimed at treating and/or preventing various 
human diseases. The documented bioactivities 
of heterocyclic compounds prompted us to 
synthesize molecules having an amalgamation of 
two heterocyclic cores, thiazole and 1,3,4-
oxadiazole, linked through an acetamide. As it is 
known that structural modifications have an 
effect on the therapeutic behavior of drugs [14], 
the molecules were synthesized with variation of 
the groups attached to the 5-position of the 1,3,4-
oxadiazole core. The whole series of compounds 
was tested against the four aforementioned 






All the chemicals and analytical grade solvents 
were purchased from Sigma Aldrich, Alfa Aesar 
(Germany) and Merck through local suppliers. 
Pre-coated silica gel Al-plates were used for TLC 
with ethyl acetate and n-hexane as solvent 
system. Spots were detected under UV light at 
254 nm. With open capillary tubes, a Gallonkamp 
apparatus was used to determine the melting 
point. IR spectra were recorded using the KBr 
pellet method on a Jasco-320-A spectrometer. 
1H-NMR spectra were recorded at 600 MHz in 
DMSO with a Bruker spectrometer. Mass spectra 
(EIMS) were obtained on a JEOL JMS-600H 
instrument with data system. The coupling 
constant (J) is given in Hz and chemical shift ( ) 
in ppm. The abbreviations used in the 
interpretation of 1H NMR spectra are as follows: 
s, singlet; d, doublet; dd, doublet of doublets; t, 
triplet; br.t, broad triplet; q, quartet; quin, quintet; 
sex, sextet; sep, septet; m, multiplet.  
 
Procedure for synthesis of 2-bromo-N-(4-
methyl-1,3-thiazol-2-yl)acetamide (3) 
 
4-Methyl-1,3-thiazol-2-amine (1;0.038 mol) was 
dissolved in 25 mL of distilled water in an iodine 
flask (100 mL) and 20 % aq. Na2CO3was added 
to adjust the pH to 9-10. 2-Bromoethanoyl 
bromide (2; 0.038 mol; bromoacetyl bromide) 
was added gradually with vigorous shaking and 
the mixture then allowed to stir for 2 h. Reaction 
completion was monitored by TLC. Excess ice-
cold distilled water (40 mL) was added, and the 
precipitate formed was collected by filtration. This 
precipitate of 3 was washed with distilled water 
and dried. 
 
General procedure for synthesis of ethyl 
aralkyl/arylcarboxylates (5a-r) 
 
Aralkyl/arylcarboxylic acids (4a-r; 2.5 g each) 
were refluxed, individually, with 60 mL of EtOH 
for 4-5 h in the presence of conc. H2SO4 (1.25 
mL) in a 250-mL round-bottom flask. TLC plates 
were used to round-bottom monitor the reactions. 
Excess distilled water (150 mL) was added after 
maximum completion of the reaction, and the pH 
was adjusted to 8-10 with 20 % aq. Na2CO3. The 
product was collected through sequential 
extraction with CHCl3 (50 mL × 3). CHCl3 was 
distilled off to collect the products. In some 
cases, the products were collected by filtration. 
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The esters obtained, 5a-r, were then used 
further. 
 
General procedure for synthesis of 
aralkyl/arylcarbohydrazides (6a-r) 
 
Ethyl esters (5a-r; 4.5 mL) were refluxed with 
80% N2H4.H2O (7.2 mL) for 3-4 h in 20 mL of 
EtOH in a round-bottom flask (100 mL). The 
reaction was monitored by TLC. At completion, 
excess ice-cold distilled H2O (60 mL) was added 
to obtain  the precipitate, which was  filtered off, 
washed with distilled H2O and dried to acquire 
the compounds, 6a-r. 
 
General procedure for synthesis of 5-
aralkyl/aryl-1,3,4-oxadiazol-2-thiol (7a-r) 
 
Solid KOH (0.029 mol) was dissolved in 25 mL of 
EtOH on reflux in a 100-mL round-bottomflask. 
Aralkyl/arylcarbohydrazides (6a-r; 0.029 mol,), 
individually, were refluxed with CS2 (0.058 mol) 
in this alkaline EtOH for 5-6 h. Reaction was 
monitored by TLC. At completion, excess ice-
cold distilled H2O (60 mL) was added to form a 
homogeneous solution.  pH was  adjusted to  5-6  
by adding dilute HCl, and the precipitate formed 
was  filtered off, washed with distilled H2O and 
dried. The products formed, 7a-r, were also re-
crystallized from EtOH.  
 





0.004 mol), individually, were dissolved in DMF 
(11 mL) in a 50-mL round-bottom flask. LiH 
(0.004 mol) was then added, and the mixture 
was stirred for 0.5 h. 2-Bromo-N-(4-methyl-1,3-
thiazol-2-yl)acetamide (3; 0.004 mol) was added 
and the mixture further stirred for 4-6 h. Reaction 
completion was confirmed by TLC. Excess ice-
cold distilled water (25 mL) was then added 
gradually to the reaction mixture   with 
continuous stirring. Aqueous NaOH was added 
dropwise with gentle shaking to adjust the pH to 
8-10. The reaction mixture was stirred for 1 h, 
and the precipitates of 8a-r were filtered off, 
washed with distilled H2O and dried. 
 
Enzyme inhibition assays 
 
Cholinesterase inhibition assay 
 
AChE and BChE inhibitory activity was 
determined in 96-well microplates according to a 
reported method [15] with slight modifications. 
The reaction mixture totaled 100 µL and 
contained the following: 60µL of 50 mM 
Na2HPO4 buffer, pH 7.7; 10 µL of 
acetylthiocholine iodide for AChE and 
butyrylthiocholine bromide for BChE, at final 
concentrations of acetylthiocholine iodide;10 µL 
of test compound at 0.5 mM,  and 10 µL of 
enzyme (0.005 U/well AChE or  BChE). The 
microplates were mixed, pre-read, and incubated 
for 10 min at 37 ºC. The enzyme reaction product 
was determined by the addition of 0.5 mM 
Ellman's reagent (5,5'-dithio-bis-[2-nitrobenzoic 
acid)and further  incubation for 15 min at 37ºC, 
followed by reading absorbance at 405 nm. All 
experiments were performed with controls and in 
triplicate. Eserine (0.5 mM) served as the 
positive control. Inhibition (H) was calculated 
using Eq 1. 
 
H (%) = {(Ac – At)/Ac}100 …………… (1) 
 
where Ac = absorbance of control and At = 
absorbance of test compound. 
 
IC50 values were calculated using EZ–Fit 
Enzyme kinetics software (Perrella Scientific Inc. 
Amherst, NH, USA). 
 
α-Glucosidase inhibition assay 
 
This enzyme inhibition assay was  carried out in 
96-well as previously reported [16], with 
modifications,  in which a 100-µL reaction 
mixture  contained  70 µL of phosphate-buffered 
saline, pH 6.8, 10 µL of test compound and 10 
µL of enzyme (p-nitrophenyl-alpha-D-
glucopyranoside U/well). 
 
The reaction mixture was mixed, incubated for 
10 min at 37 ºC and pre-read at 400nm. The 
reaction was initiated by the addition of 10 µL of 
0.5 mM p-nitrophenyl-alpha-D-glucopyranoside. 
Acarbose was used as positive control. 
Microplates were incubated for 30 min at37 ºC 
and absorbance read at 400 nm using a Synergy 
HT microplate reader. All experiments were 
performed in duplicate. The equation discussed 
for cholinesterase enzymes was used for the 
determination of % inhibition and IC50 values. 
 
Urease inhibition assay 
 
This enzyme inhibition assay is the customized 
form of the commonly known Berthelot assay 
[17]. To each well of a 96-well microplate, 45 µL 
of reaction mixture containing 10μL of phosphate 
buffer, pH 7.0, 10μL of test sample and 25μL of 
urease solution (0.135 U) were added. Contents 
were pre-incubated at 37 ºC for 5 min. A volume 
(40μL) of urea stock solution (20 mM) was added 
to each well, and the microplate incubated for 10 
min at 37ºC. This was followed by the addition of 
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115μL of phenol-hypochlorite reagent (freshly 
prepared by mixing 45μL phenol with 70 μL of 
alkali) per well. For color development, the 
microplate was incubated for another 10 min at 
37 ºC, and absorbance measured at 625 nm. 
The percentage enzyme inhibition and IC50 




Cytotoxicity was evaluated by the brine shrimp 
lethality bioassay [18]. Artificial sea water was 
prepared with sea salt at 34g/L.A shallow 
rectangular dish (22×32 cm) was used for the 
hatching of brine shrimp (Artemia salina) eggs 
(Sera, Heidelberg, Germany) under constant 
aeration for 48 h at room temperature. After 
hatching, active shrimp were collected from the 
brighter portion of the hatching chamber and 
used for the assay. Vials containing 5 mL of 
artificial sea water (with different concentrations 
of test compounds from the stock) were used. 
Ten shrimp were transferred to each vial. The 
temperature of the vials was maintained at 26 
°C. The number of surviving shrimp were 
calculated after one day. The experiment was 
performed in triplicate and data analyzed with the 
Finney computer program to determine the LD50 
(lethal dose that killed 50 % of shrimp). 
 
Molecular docking studies 
 
The reported MOE-Dock method of MOE 2009-
2010 was utilized to study molecular recognition 
[19]. The Protein Data Bank site was used to 
retrieve protein molecules of 
acetylcholinesterase (PDB code: 1GQR), 
butyrylcholinesterase (PDB code: 1POP), α-
glucosidase (PDB ID: 3NO4) and urease (PDB 
ID: 4UBP). After removing water molecules, 
MOE applications were used for performing 3D 
protonation of the protein molecule. The energy 
minimization algorithm of the MOE tool was used 
to minimize the energy of protein molecules 
using the following parameters; gradient of 0.05, 
Force Field of MMFF94X & Solvation and Chiral 
Constraint of Current Geometry. However, 
minimization of energy was ended for the 
gradient below 0.05. The templates for docking 
were the energy minimized protonated structures 
that were saved in a separate database (using a 
mdb file format). Finally, all compounds were 
docked into the binding pockets of enzymes. For 
the confirmation of validity, a re-docking 
procedure was applied. After docking analysis of 
each compound with 30 conformations, the best 
2D images were selected for their specific types 
of interactions and their 3D images were drawn 
along with their bond lengths. 
 
Statistical analysis    
 
All measurements were carried out in triplicate 
and statistical analysis was performed by 
Microsoft Excel 2010. The results are presented 
as mean ± SEM with 90 % CL. P < 0.05 was 
considered statistically significant. 
 




The protocol for the synthesis of the new 
molecules, 2-{[5-(aralkyl/aryl)-1,3,4-oxadiazol-2-
yl]sulfanyl}-N-(4-methyl-1,3-thiazol-2-yl) 
acetamides (8a-r), is sketched in Figure 1, and 
the various  groups are given in Table 1. The first 
step in the synthesis was the reaction of 4-
methyl-1,3-thiazol-2-amine (1) with 2-
bromoethanoyl bromide (2) in a basic aqueous 
medium to synthesize 2-bromo-N-(4-methyl-1,3-
thiazol-2-yl)acetamide (3), an electrophile. 
Various nucleophiles were then synthesized in a 
parallel sequence of reactions, starting from a 
series of aralkyl/arylcarboxylic acids, 4a-r, which 
were converted to respective esters, 5a-r; acid 
hydrazides, 6a-r, which were cyclized to the 
respective 5-aralkyl/aryl-1,3,4-oxadiazole-2-thiols 
(7a-r). These thiols, serving as nucleophiles, 
were finally coupled one by one with 3in an 
aprotic polar solvent, i.e., DMF, using LiH as a 
base to obtain the target heterocyclic derivatives, 
8a-r. The structural verification was performed 
through spectral data analysis. All compounds 
were tested for enzyme inhibitory activity against 
cholinesterases, urease, and α-glucosidase, and 
the results are as shown in Table 2. The brine 
shrimp lethality bioassay was used to evaluate 
the cytotoxicity of the synthesized compounds 
and these results are given in Table 3. 
 






Dull-white solid; yield: 80%; m.p.: 176-177 oC 
Mol. Formula: C14H12N4O2S2; Mol. Mass: 332 
g/mol; IR (KBr, cm-1) ʋmax: 3347 (N-H stretching), 
2976 (C-H stretching of aromatic ring), 1678 
(C=N stretching), 1644 (C=O stretching), 1570 
(C=C stretching of aromatic ring), 1154 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.47 (s, 1H, CON-H), 7.93 (d, J = 8.5 
Hz,2H, H-2''' & H-6'''), 7.62-7.57 (m, 3H, H-3''' to 
H-5'''), 6.80 (br.s, 1H, H-5), 4.38 (br.s, 2H, CH2-
2'), 2.27 (s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 
MHz, δ/ppm): δ 165.76 (C-1'), 165.26 (C-5''), 
162.98 (C-2''), 156.86 (C-2), 146.88 (C-4),  
Ramzan et al 












































































Figure 1:  Protocol for synthesis of 2-{[5-(aralkyl/aryl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(4-methyl-1,3-thiazol-2-
yl)acetamides 
 
132.06 (C-4'''), 129.38 (C-3''' & C-5'''), 126.36 (C-
2''' & C-6'''), 122.89 (C-1'''), 108.12 (C-5), 35.37 
(C-2'), 16.83 (C-6); EI-MS: m/z 332 [M]+, 219 
[C10H7N2O2S]+, 192 [C9H7N2OS]+, 114 






Light-brown solid; yield: 79%; m.p.: 227-228 oC; 
Mol. Formula: C15H14N4O2S2; Mol. Mass: 346 
g/mol; IR (KBr, cm-1) ʋmax: 3358 (N-H stretching), 
2977 (C-H stretching of aromatic ring), 1675 
(C=N stretching), 1645 (C=O stretching), 1576 
(C=C stretching of aromatic ring), 1169 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.46 (s, 1H, CON-H), 7.82 (br.d, J = 
8.1 Hz, 2H, H-2''' & H-6'''), 7.38 (br.d, J = 7.8 Hz, 
2H, H-3''' & H-5'''), 6.79 (br.s, 1H, H-5), 4.37 
(br.s, 2H, CH2-2'), 2.38 (s, 3H, CH3-7'''), 2.27 (s, 
3H, CH3-6); 13C-NMR (DMSO-d6, 150 MHz, 
δ/ppm): δ 165.35 (C-1'), 164.35 (C-5''), 162.60 
(C-2''), 156.7 (C-2), 142.25 (C-4), 141.0 (C-4'''), 
129.92 (C-2''' & C-6'''), 126.32 (C-3''' & C-5'''), 
120.15 (C-1'''), 108.06 (C-5), 35.41 (C-2'), 21.09 
(C-7'''), 11.07 (C-6) ; EI-MS: m/z 346 [M]+, 233 
[C11H9N2O2S]+, 206 [C10H9N2OS]+, 192 
[C8H5N3OS]+, 159 [C9H7N2O]+, 141 [C5H5N2OS]+, 







Dull-white solid; yield: 80%; m.p.: 186-187 oC; 
Mol. Formula: C14H12N4O3S2; Mol. Mass: 348 
g/mol; IR (KBr, cm-1) ʋmax: 3356 (N-H stretching), 
2979 (C-H stretching of aromatic ring), 1667 
(C=N stretching), 1646 (C=O stretching), 1571 
(C=C stretching of aromatic ring), 1148 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.43 (s, 1H, CON-H), 7.96 (br.d, J = 
8.5 Hz, 2H, H-3''' & H-5'''), 7.91 (br.d, J = 8.5 Hz, 
1H, H-2''' & H-6'''), 6.79 (s, 1H, H-5), 4.30 (br.s, 
2H, CH2-2'), 2.27 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.15 (C-1'), 
163.70 (C-5''), 163.32 (C-2''), 157.65 (C-2), 
146.81 (C-4), 137.81 (C-3''' & C-5'''), 133.28 (C-
4'''), 131.14 (C-2''' & C-6'''), 122.07 (C-1'''), 
108.05 (C-5), 35.38 (C-2'), 16.83 (C-6); EI-MS: 
m/z 348 [M]+, 235 [C10H7N2O3S]+, 228 
[C7H7N3O2S2]+, 208 [C9H8N2O2S]+, 175 
[C9H7N2O2]+, 161 [C9H9N2O]+, 141 [C5H5N2OS]+, 
121 [C7H5O2]+, 114 [C4H5N2S]+, 93 [C6H5O]+. 
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Table 1: Different aralkyl/aryl groups in 2-{[5-(aralkyl/aryl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(4-methyl-1,3-thiazol-
2-yl)acetamides (8a-r) 
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Protocol for synthesis of 2-{[5-(aralkyl/aryl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(4-methyl-1,3-thiazol-2-yl)acetamides 
(8a-r). Reagents & conditions: (1) H2O, 20 % Na2CO3, stirring for 2 h. (2) H2SO4, EtOH, refluxing for 4-5 h. (3) 






Light-brown solid; yield: 75%; m.p.: 157-158 oC; 
Mol. Formula: C15H14N4O3S2; Mol. Mass: 362 
g/mol; IR (KBr, cm-1) ʋmax: 3358 (N-H stretching), 
2977 (C-H stretching of aromatic ring), 1674 
(C=N stretching), 1644 (C=O stretching), 1575 
(C=C stretching of aromatic ring), 1163 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.46 (s, 1H, CON-H), 7.76 (dd, J = 
1.5, 7.6 Hz, 1H, H-6'''), 7.60 (dt, J = 1.5, 8.6 Hz, 
1H, H-5'''), 7.24 (br.d, J = 8.4 Hz, 1H, H-3'''), 7.09 
(br.t, J = 7.5 Hz, 1H, H-4'''), 6.80 (s, 1H, H-5), 
4.38 (br.s, 2H, CH2-2'), 3.85 (br.s, 3H, CH3O-7'''), 
2.27 (s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 
MHz, δ/ppm): δ 165.15 (C-1'), 164.0 (C-5''), 
162.71 (C-2''), 157.86 (C-2'''), 156.92 (C-2), 
146.85 (C-4), 133.60 (C-5'''), 133.01 (C-6'''), 
120.68 (C-4'''), 112.62 (C-3'''), 111.79 (C-1'''), 
108.06 (C-5), 55.92 (C-7'''), 35.34 (C-2'), 16.81 
(C-6); EI-MS: m/z 362 [M]+, 257 [C8H9N4O2S2]+, 
249 [C11H9N2O3S]+, 222 [C10H9N2O2S]+, 189 
[C6H9N2OS2]+, 175 [C9H7N2O2]+, 161 [C9H9N2O]+, 
141 [C5H5N2OS]+, 135 [C8H7O]+, 114 






Light-brown solid; yield: 77%; m.p.: 158-159 oC; 
Mol. Formula: C14H11ClN4O2S2; Mol. Mass: 366 
g/mol; IR (KBr, cm-1) ʋmax: 3350 (N-H stretching), 
2973 (C-H stretching of aromatic ring), 1670 
(C=N stretching), 1640 (C=O stretching), 1572 
(C=C stretching of aromatic ring), 1159 (C-O-C 
stretching), 684 (C-Cl stretching); 1H-NMR 
(DMSO-d6, 600 MHz, δ/ppm): δ 12.47 (s, 1H, 
CON-H), 7.94 (dd, J = 1.6, 7.8 Hz, 1H, H-3'''), 
7.69 (br.d, J = 7.9 Hz, 1H, H-6'''), 7.62 (dt, J = 
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1.6, 8.1 Hz, 1H, H-4'''), 7.53 (dt, J = 0.9, 6.6 Hz, 
1H, H-5'''), 6.80 (br.s, 1H, H-5), 4.40 (br.s, 2H, 
CH2-2'), 2.27 (s, 3H, CH3-6); 13C-NMR (DMSO-
d6, 150 MHz, δ/ppm): δ 165.01 (C-1'), 163.39 (C-
5''), 163.30 (C-2''), 156.66 (C-2), 146.87 (C-4), 
133.30 (C-4'''), 131.66 (C-2'''), 131.14 (C-3'''), 
131.10 (C-6'''), 127.82 (C-5'''), 122.06 (C-1'''), 
108.12 (C-5), 35.39 (C-2'), 16.84 (C-6); EI-MS: 
m/z 368 [M+2]+, 366 [M]+, 253 [C10H6ClN2O2S]+, 
226 [C9H6ClN2OS]+, 193 [C8H6N3OS]+, 179 
[C8H4ClN2OS]+, 139 [C5H3N2OS]+, 125 [C7H5Cl]+, 






Light-brown solid; yield: 79%; m.p.: 189-190 oC; 
Mol. Formula: C14H11ClN4O2S2; Mol. Mass: 366 
g/mol; IR (KBr, cm-1) ʋmax: 3368 (N-H stretching), 
2979 (C-H stretching of aromatic ring), 1674 
(C=N stretching), 1646 (C=O stretching), 1571 
(C=C stretching of aromatic ring), 1155 (C-O-C 
stretching), 689 (C-Cl stretching); 1H-NMR 
(DMSO-d6, 600 MHz, δ/ppm): δ 12.47 (s, 1H, 
CON-H), 7.98 (dd, J = 2.1, 8.5 Hz, 1H, H-6'''), 
7.96 (br.t, J = 8.5 Hz, 1H, H-5'''), 7.52 (d, J = 2.1 
Hz, 1H, H-2'''), 7.49 (dd, J = 2.1, 8.5 Hz, 1H, H-
4'''), 6.80 (br.s, 1H, H-5), 4.40 (br.s, 2H, CH2-2'), 
2.27 (s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 
MHz, δ/ppm): δ 165.15 (C-1'), 163.70 (C-5''), 
163.32 (C-2''), 157.65 (C-2), 146.81 (C-4), 
137.81 (C-3'''), 133.28 (C-4'''), 131.14 (C-2'''), 
131.09 (C-6'''), 127.82 (C-5'''), 122.07 (C-1'''), 
108.12 (C-5), 35.38 (C-2'), 16.84 (C-6); EI-MS: 
m/z 366 [M]+, 226 [C9H6ClN2OS]+, 193 
[C8H6N3OS]+, 179 [C8H4ClN2OS]+, 139 
[C5H3N2OS]+, 125 [C7H5Cl]+, 114 [C3H2N2OS]+, 






Light-brown solid; yield: 76%; m.p.: 187-188 oC; 
Mol. Formula: C14H11ClN4O2S2; Mol. Mass: 366 
g/mol; IR (KBr, cm-1) ʋmax: 3347 (N-H stretching), 
2979 (C-H stretching of aromatic ring), 1681 
(C=N stretching), 1636 (C=O stretching), 1584 
(C=C stretching of aromatic ring), 1165 (C-O-C 
stretching), 691 (C-Cl stretching); 1H-NMR 
(DMSO-d6, 600 MHz, δ/ppm): δ 12.47 (s, 1H, 
CON-H), 7.91 (br.d, J = 8.5 Hz, 2H, H-2''' & H-
6'''), 7.49 (br.d, J = 8.5 Hz, 1H, H-3''' & H-5'''), 
6.80 (br.s, 1H, H-5), 4.40 (br.s, 2H, CH2-2'), 2.27 
(s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 MHz, 
δ/ppm): δ 165.15 (C-1'), 163.70 (C-5''), 163.32 
(C-2''), 157.65 (C-2), 146.81 (C-4), 137.81 (C-3''' 
& C-5'''), 133.28 (C-4'''), 131.14 (C-2''' & C-6'''), 
122.07 (C-1'''), 108.09 (C-5), 35.38 (C-2'), 16.80 
(C-6); EI-MS: m/z 366 [M]+, 226 [C9H6ClN2OS]+,  
179 [C8H4ClN2OS]+, 139 [C5H3N2OS]+, 125 






Light-brown solid; yield: 77%; m.p.: 168-169 oC; 
Mol. Formula: C14H10Cl2N4O2S2; Mol. Mass: 400 
g/mol; IR (KBr, cm-1) ʋmax: 3379 (N-H stretching), 
2982 (C-H stretching of aromatic ring), 1677 
(C=N stretching), 1647 (C=O stretching), 1575 
(C=C stretching of aromatic ring), 1164 (C-O-C 
stretching), 694 (C-Cl stretching); 1H-NMR 
(DMSO-d6, 600 MHz, δ/ppm): δ 12.47 (s, 1H, 
CON-H), 7.96 (br.d, J = 8.5 Hz, 1H, H-6'''), 7.90 
(d, J = 1.8 Hz, 1H, H-3'''), 7.64 (dd, J = 1.6, 8.4 
Hz, 1H, H-5'''), 6.80 (br.s, 1H, H-5), 4.41 (br.s, 
2H, CH2-2'), 2.27 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.01 (C-1'), 
163.88 (C-5''), 162.65 (C-2''), 156.89 (C-2), 
146.81 (C-4), 137.19 (C-4'''), 132.73 (C-2'''), 
132.23 (C-6'''), 130.72 (C-3'''), 128.13 (C-5'''), 
121.06 (C-1'''), 108.09 (C-5), 35.43 (C-2'), 16.80 
(C-6); EI-MS: m/z 404 [M+4]+, 402 [M+2]+, m/z 
400 [M]+, 260 [C9H5ClN2O2S]+, 172 [C7H3Cl2N]+, 







White amorphous solid; yield: 83%; m.p.: 190-
191 oC; Mol. Formula: C14H13N5O2S2; Mol. Mass: 
347 g/mol; IR (KBr, cm-1) ʋmax: 3378 (N-H 
stretching), 2962 (C-H stretching of aromatic 
ring), 1680 (C=N stretching), 1653 (C=O 
stretching), 1566 (C=C stretching of aromatic 
ring), 1164 (C-O-C stretching); 1H-NMR (DMSO-
d6, 600 MHz, δ/ppm): δ 12.43 (s, 1H, CON-H), 
7.93 (dd, J = 2.1, 8.5 Hz, 1H, H-6'''), 7.88 (br.t, J 
= 8.5 Hz, 1H, H-5'''), 7.48 (d, J = 2.1 Hz, 1H, H-
2'''), 7.47 (dd, J = 2.1, 8.5 Hz, 1H, H-4'''), 6.79 (s, 
1H, H-5), 4.30 (br.s, 2H, CH2-2'), 2.27 (s, 3H, 
CH3-6); 13C-NMR (DMSO-d6, 150 MHz, δ/ppm): δ 
165.26 (C-1'), 162.99 (C-5''), 160.46 (C-2''), 
157.71 (C-2), 146.80 (C-4), 132.21 (C-3'''), 
132.04 (C-1'''), 129.41 (C-5'''), 129.38 (C-6'''), 
126.35 (C-4'''), 126.02 (C-2'''), 108.05 (C-5), 
35.36 (C-2'), 16.84 (C-6); EI-MS: m/z 347 [M]+, 
207 [C9H8N3OS]+, 193 [C8H6N3OS]+, 141 
[C5H5N2OS]+, 133 [C8H7NO]+, 118 [C3HNOS]+, 92 
[C6H6N]+, 65 [C5H5]+. 
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White amorphous solid; yield: 82%; m.p.: 215-
216 oC; Mol. Formula: C14H13N5O2S2; Mol. Mass: 
347 g/mol; IR (KBr, cm-1) ʋmax: 3376 (N-H 
stretching), 2966 (C-H stretching of aromatic 
ring), 1683 (C=N stretching), 1657 (C=O 
stretching), 1563 (C=C stretching of aromatic 
ring), 1168 (C-O-C stretching); 1H-NMR (DMSO-
d6, 600 MHz, δ/ppm): δ 12.43 (s, 1H, CON-H), 
7.56 (br.d, J = 8.5 Hz, 2H, H-2''' & H-6'''), 6.79 (s, 
1H, H-5), 6.63 (br.d, J = 8.6 Hz, 2H, H-3''' & H-
5'''), 4.30 (br.s, 2H, CH2-2'), 2.27 (s, 3H, CH3-6); 
13C-NMR (DMSO-d6, 150 MHz, δ/ppm): δ 166.11 
(C-1'), 165.39 (C-5''), 160.54 (C-2''), 156.88 (C-
2), 152.40 (C-4'''), 146.90 (C-4), 127.90 (C-2''' & 
C-6'''), 113.46 (C-3''' & C-5'''), 109.13 (C-1'''), 
108.00 (C-5), 35.31 (C-2'), 16.84 (C-6); EI-MS: 
m/z 347 [M]+, 207 [C9H8N3OS], 193 [C8H6N3OS], 
160 [C8H6N3O]+, 141 [C5H5N2OS], 133 [C8H7NO], 






Light-yellow solid; yield: 77%; m.p.: 170-171 oC; 
Mol. Formula: C14H11N5O4S2; Mol. Mass: 377 
g/mol; IR (KBr, cm-1) ʋmax: 3364 (N-H stretching), 
2982 (C-H stretching of aromatic ring), 1673 
(C=N stretching), 1649 (C=O stretching), 1578 
(C=C stretching of aromatic ring), 1157 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.47 (s, 1H, CON-H), 8.19-8.17 (m, 
1H, H-3'''), 8.01-7.97 (m, 1H, H-6'''), 7.94-7.90 
(m, 2H, H-4''' & H-5'''), 6.80 (br.s, 1H, H-5), 4.41 
(br.s, 2H, CH2-2'), 2.27 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 164.91 (C-1'), 
164.41 (C-5''), 161.69 (C-2''), 156.70 (C-2), 
147.66 (C-2'''), 146.84 (C-4), 133.67 (C-4'''), 
133.50 (C-5'''), 131.50 (C-3'''), 124.77 (C-6'''), 
116.49 (C-1'''), 108.09 (C-5), 35.48 (C-2'), 16.81 
(C-6); EI-MS: m/z 377 [M]+, 227 [C8H7N2O2S2]+, 






Light-yellow solid; yield: 78%; m.p.: 194-195 oC; 
Mol. Formula: C14H11N5O4S2; Mol. Mass: 377 
g/mol; IR (KBr, cm-1) ʋmax: 3360 (N-H stretching), 
2963 (C-H stretching of aromatic ring), 1660 
(C=N stretching), 1650 (C=O stretching), 1562 
(C=C stretching of aromatic ring), 1169 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.48 (s, 1H, CON-H), 8.63 (br.s, J = 
7.7 Hz, 1H, H-2'''), 8.46 (dd, J = 1.8, 8.2 Hz, 1H, 
H-4'''), 8.37 (br.d, J = 7.8 Hz, 1H, H-6'''), 7.88 
(br.t, 1H, H-5'''), 6.79 (br.s, 1H, H-5), 4.40 (br.s, 
2H, CH2-2'), 2.26 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.12 (C-1'), 
163.97 (C-5''), 163.70 (C-2''), 157.63 (C-2), 
148.17 (C-3'''), 148.15 (C-4), 126.30 (C-4'''), 
131.23 (C-5'''), 132.34 (C-6'''), 124.33 (C-1'''), 
120.82 (C-2'''), 108.91 (C-5), 35.36 (C-2'), 16.73 
(C-6); EI-MS: m/z 377 [M]+, 227 [C8H7N2O2S2]+, 
150[C7H4NO3]+, 141 [C5H5N2OS]+, 114 






Light-yellow solid; yield: 77%; m.p.: 173-174 oC; 
Mol. Formula: C14H11N5O4S2; Mol. Mass: 377 
g/mol; IR (KBr, cm-1) ʋmax: 3364 (N-H stretching), 
2987 (C-H stretching of aromatic ring), 1684 
(C=N stretching), 1654 (C=O stretching), 1586 
(C=C stretching of aromatic ring), 1173 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.48 (s, 1H, CON-H), 8.42 (br.d, J = 
7.0 Hz, 1H, H-3''' & H-5'''), 8.21 (br.d, J = 7.0 Hz, 
2H, H-2''' & H-6'''), 6.79 (br.s, 1H, H-5), 4.40 
(br.s, 2H, CH2-2'), 2.26 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.00 (C-1'), 
164.51 (C-5''), 163.93 (C-2''), 156.01 (C-2), 
149.15 (C-4'''), 148.15 (C-4), 127.74 (C-2''' & C-
6'''), 124.58 (C-3''' & C-5'''), 122.01 (C-1'''), 
108.12 (C-5), 35.38 (C-2'), 16.73 (C-6); EI-MS: 
m/z 377 [M]+, 227 [C8H7N2O2S2]+, 
150[C7H4NO3]+, 141 [C5H5N2OS]+, 114 






Light-green solid; yield: 74%; m.p.: 215-216 oC; 
Mol. Formula: C14H10N6O6S2; Mol. Mass: 422 
g/mol; IR (KBr, cm-1) ʋmax: 3366 (N-H stretching), 
2985 (C-H stretching of aromatic ring), 1685 
(C=N stretching), 1658 (C=O stretching), 1589 
(C=C stretching of aromatic ring), 1192 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.48 (s, 1H, CON-H), 7.98 (br.d, J = 
1.6 Hz, 2H, H-2''' & H-6'''), 7.66 (br.s, 1H, H-4'''), 
6.79 (br.s, 1H, H-5), 4.40 (br.s, 2H, CH2-2'), 2.26 
(s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 MHz, 
δ/ppm): δ 165.12 (C-1'), 163.88 (C-5''), 162.67 
(C-2''), 157.71 (C-2), 145.23 (C-4), 132.60 (C-
1'''), 132.24 (C-2''' & C-6'''), 131.97 (C-3''' & C-
5'''), 128.19 (C-4'''), 108.91 (C-5), 35.40 (C-2'), 
16.70 (C-6); EI-MS: m/z 422 [M]+, 303 
[C12H8N4O2S2]+, 193 [C8H6N3OS]+, 140 
[C5H5N2OS]+, 114 [C3H2N2OS]+, 104 [C7H4O]+, 76 
[C6H4]+. 
 
Ramzan et al 






Light-brown solid; yield: 71%; m.p.: 191-192 oC; 
Mol. Formula: C15H12N6O6S2; Mol. Mass: 436 
g/mol; IR (KBr, cm-1) ʋmax: 3346 (N-H stretching), 
2969 (C-H stretching of aromatic ring), 1665 
(C=N stretching), 1636 (C=O stretching), 1568 
(C=C stretching of aromatic ring), 1152 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.40 (s, 1H, CON-H), 7.90 (d, J = 2.8 
Hz, 1H, H-4'''), 7.64 (d, J = 2.8 Hz, 1H, H-6'''), 
6.79 (br.s, 1H, H-5), 4.24 (br.s, 2H, CH2-2'), 2.34 
(br.s, 3H, CH3-7'''), 2.27 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.12 (C-1'), 
163.88 (C-5''), 162.67 (C-2''), 157.71 (C-2), 
146.88 (C-4), 132.60 (C-1'''), 132.24 (C-6'''), 
131.97 (C-5'''), 130.81 (C-3'''), 128.19 (C-4'''), 
128.14 (C-2'''), 108.07 (C-5), 35.40 (C-2'), 20.67 
(C-7'''), 16.82 (C-6'''); EI-MS: m/z 436 [M]+, 303 
[C12H8N4O2S2]+, 281 [C9H5N4O5S]+, 193 
[C8H6N3OS]+, 181 [C7H5N2O4]+, 140 






Light-brown solid; yield: 77%; m.p.: 177-178 oC; 
Mol. Formula: C14H9ClN6O6S2; Mol. Mass: 456 
g/mol; IR (KBr, cm-1) ʋmax: 3354 (N-H stretching), 
2978 (C-H stretching of aromatic ring), 1674 
(C=N stretching), 1645 (C=O stretching), 1576 
(C=C stretching of aromatic ring), 1163 (C-O-C 
stretching), 693 (C-Cl stretching); 1H-NMR 
(DMSO-d6, 600 MHz, δ/ppm): δ 12.40 (s, 1H, 
CON-H), 7.91 (d, J = 2.6 Hz, 1H, H-4'''), 7.68 (d, 
J = 2.6 Hz, 1H, H-6'''), 6.79 (br.s, 1H, H-5), 4.24 
(br.s, 2H, CH2-2'), 2.27 (s, 3H, CH3-6); 13C-NMR 
(DMSO-d6, 150 MHz, δ/ppm): δ 165.12 (C-1'), 
163.88 (C-5''), 162.67 (C-2''), 157.71 (C-2), 
147.88 (C-4), 132.60 (C-1'''), 132.24 (C-6'''), 
131.97 (C-5'''), 130.81 (C-3'''), 128.19 (C-4'''), 
128.14 (C-2'''), 108.07 (C-5), 35.40 (C-2'), 16.82 
(C-6); EI-MS: m/z 456 [M]+, 303 [C12H8N4O2S2]+, 
302 [C8H2ClN4O5S]+, 227 [C9H6ClN2OS]+, 201 
[C6H2ClN2O4]+, 193 [C8H6N3OS]+, 141 






Dull-white solid; yield: 80%; m.p.: 178-179 oC, 
Mol. Formula: C15H14N4O2S2; Mol. Mass: 346 
g/mol; IR (KBr, cm-1) ʋmax: 3357 (N-H stretching), 
2974 (C-H stretching of aromatic ring), 1682 
(C=N stretching), 1646 (C=O stretching), 1582 
(C=C stretching of aromatic ring), 1166 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.40 (s, 1H, CON-H), 7.32-7.25 (m, 
5H, H-2''' to H-6'''), 6.79 (br.s, 1H, H-5), 4.33 
(br.s, 2H, CH2-7'''), 4.24 (br.s, 2H, CH2-2'), 2.27 
(s, 3H, CH3-6); 13C-NMR (DMSO-d6, 150 MHz, 
δ/ppm): δ 166.73 (C-1'), 165.01 (C-5''), 162.38 
(C-2''), 157.01 (C-2), 147.01 (C-4), 134.13 (C-
1'''), 128.79 (C-3''' & C-5'''), 128.69 (C-2''' & C-
6'''), 127.22 (C-4'''), 108.07 (C-5), 35.27 (C-2'), 
30.67 (C-7'''), 16.82 (C-6); EI-MS: m/z 346 [M]+, 
255 [C8H7N4O2S]+, 228 [C7H7N4OS2]+, 206 
[C10H9N2OS]+, 192 [C8H5N3OS]+, 141 







Light-yellow solid; yield: 78%; m.p.: 206-207 oC; 
Mol. Formula: C18H14N4O2S2; Mol. Mass: 382 
g/mol; IR (KBr, cm-1) ʋmax: 3359 (N-H stretching), 
2978 (C-H stretching of aromatic ring), 1677 
(C=N stretching), 1646 (C=O stretching), 1579 
(C=C stretching of aromatic ring), 1163 (C-O-C 
stretching); 1H-NMR (DMSO-d6, 600 MHz, 
δ/ppm): δ 12.40 (s, 1H, CON-H), 8.07 (br.d, J = 
7.9 Hz, 1H, H-6'''), 7.95 (dist.dd, J = 1.5, 7.4 Hz, 
1H, H-5'''), 7.88 (dist.dd, J = 1.5, 7.1 Hz, 1H, H-
4'''), 7.57-7.53 (m, 2H, H-7''' & H-8'''), 7.48-7.44 
(m, 2H, H-2'''& H-3'''), 6.79 (br.s, 1H, H-5), 4.59 
(s, 2H, CH2-11'''), 4.24 (br.s, 2H, CH2-2'), 2.27 (s, 
3H, CH3-6); 13C-NMR (DMSO-d6, 150 MHz, 
δ/ppm): δ 166.73 (C-1'), 164.96 (C-5''), 164.76 
(C-2''), 155.76 (C-2), 148.56 (C-1'''), 147.0 (C-4), 
133.39 (C-7'''), 131.22 ( C-6'''), 130.22 (C-3'''), 
128.56 (C-4'''), 128.11 (C-5'''), 127.63 (C-8'''), 
126.50 (C-2'''), 125.98 (C-9'''), 123.62 (C-10'''), 
108.07 (C-5), 35.24 (C-2'), 28.44 (C-11'''), 16.82 
(C-6); EI-MS: m/z 382 [M]+, 255 [C8H7N4O2S]+, 
228 [C7H7N4OS2]+, 242 [C13H10N2OS]+, 241 
[C13H9N2OS]+, 141 [C5H5N2OS]+, 114 




In the search for new more effective therapeutic 
agents, the synthesized bi-heterocycles 8a-p 
were screened for their inhibitory activity against 
four pharmacologically relevant enzymes: 
acetylcholinesterase, butyrylcholinesterase, 
urease and α-glucosidase. The results of 
enzyme inhibition are represented as % inhibition 
and IC50 for cholinesterases, urease, glucosidase 
(Table 2) and LD50 values for brine shrimps 
(Table 3).  
 
The structural verification was performed by 
spectral analysis. The structures of these 
derivatives were deduced based on IR, EI-MS,  
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Table 2: Inhibition (%) and IC50 values for acetylcholinesterase, butyrylcholinesterase, α-glucosidase and urease. 
 
Compd. AChE inhibition BChE inhibition α- Glucosidase inhibition Urease inhibition 
 Inhibition (%) at 0.5 mM IC50 (µM) 
Inhibition (%) 
at 0.5 mM IC50 (µM) 
Inhibition (%) 
at 0.5 mM IC50 (μM) 
Inhibition (%) 
at 0.5 mM IC50 (μM) 
8a 36.12±0.19 - 36.52±0.29 - 56.21±0.30 112.13±0.16 46.52±0.19 - 
8b 84.31±0.24 43.85±0.12 47.27±0.26 - 67.14±0.19 342.13±0.16 69.31±0.31 254.11±0.12 
8c 89.31±0.35 49.25±0.09 58.14±0.25 129.15±0.11 51.32±0.14 > 500 77.13±0.20 291.47±0.19 
8d 86.52±0.29 39.47±0.13 54.62±0.34 438.52±0.22 32.25±0.13 - 56.95±0.37 223.15±0.14 
8e 86.28±0.36 49.73±0.15 12.23±0.35 - 86.41±0.17 192.27±0.14 76.31±0.50 250.30±0.25 
8f 83.74±0.23 53.15±0.25 45.27±0.35 - 79.11±0.21 187.35±0.11 92.35±0.31 161.26±0.23 
8g 77.31±0.15 79.25±0.05 45.14±0.35 - 77.23±0.19 201.23±0.21 30.61±0.29 228.13±0.14 
8h 71.36±0.64 119.53±0.21 71.42±0.45 238.64±0.18 78.12±0.18 107.42±0.12 41.56±0.15 - 
8i 92.53±0.45 72.85±0.24 52.74±0.63 464.27±0.19 87.15±0.19 156.29±0.15 67.28±0.41 212.31±0.12 
8j 87.85±0.42 92.74±0.15 79.26±0.15 67.85±0.11 82.11±0.18 278.21±0.15 - - 
8k 87.61±0.27 29.53±0.12 82.47±0.16 56.23±0.09 31.13±0.15 - - - 
8l 91.74±0.13 17.25±0.07 15.47±0.27 - 91.83±0.15 62.23±0.13 10.26±0.20 - 
8m 90.71±0.14 36.84±0.08 67.35±0.36 109.25±0.21 91.48±0.15 61.25±0.11 49.24±0.51 - 
8n 87.21±0.32 63.80±0.45 38.27±0.29 - 77.51±0.55 287.13±0.12 47.28±0.15 - 
8o 90.12±0.29 49.47±0.13 58.62±0.34 238.52±0.22 91.59±0.23 57.35±0.17 60.54±0.17 249.35±0.15 
8p 66.42±0.17 59.47±0.25 78.62±0.34 137.52±0.22 63.48±0.17 293.15±0.19 35.67±0.10 - 
8q 89.27±0.15 18.36±0.08 65.15±0.45 292.14±0.16 52.15±0.17 > 500 61.45±0.40 247.35±0.18 
8r 37.50±0.23 - - - 69.24±0.27 77.35±0.11 27.52±0.19 - 
Eserine 91.27±1.17 0.04±0.0001 82.82±1.09 0.85±0.0001     
Acarbose  92.23±0.16 37.38±0.12   
Thiourea  98.12±0.18 21.11±0.12 
Note: All compounds were dissolved in methanol and experiments were performed in triplicate (mean ± SEM, n = 
3). AChE = acetylcholinesterase, BChE =butyrylcholinesterase. 
 
Table 3: Brine shrimp activity 
 
Compd. LD50 (mM) Compd. LD50 (mM) Compd. LD50 (mM) Compd. LD50 (mM) 
8a 45.21 8f 243.6 8k 358.4 8p 201.1 
8b 213.5 8g 354.4 8l 466.7 8q 198.5 
8c 122.7 8h 395.4 8m 77.34 8r 61.47 
8d 498.7 8i 459.7 8n 171.8 Doxo- 
rubicin 5.21 8e 521.1 8j 365.8 8o 189.7 
Note: Doxorubicin was used as standard 
 
1H-NMR and 13C-NMR spectral data. The 
structural analysis of one of the compounds is 
discussed here in detail for the convenience of 
the readers. The molecule, 8e, was obtained as 
a light-brown solid with 77 % yield and had a 
melting point of 158-159 oC. Its molecular 
formula, C14H11ClN4O2S2, was established by 
identifying the [M]+ ion peak at m/z 366, in the EI-
MS spectrum and counting the number of 
protons in  the 1H-NMR spectrum. The number of 
carbons in the 13C-NMR spectrum also supported 
the assignment of its molecular formula. In the 
EI-MS spectrum, the peak at m/z 368 was 
identified as the [M+2]+ peak, while the molecular 
ion peak was observed at m/z 366 along with 
some peculiar fragment ion peaks as indicated in 
the spectral characterization section. The 2-
chlorophenyl moiety in the molecule was 
rationalized by four typical signals in the aromatic 
region of  the 1H-NMR spectrum (Figure 2) at δ 
7.94 (dd, J = 1.6, 7.8 Hz, 1H, H-3'''), 7.69 (br.d, J 
= 7.9 Hz, 1H, H-6'''), 7.62 (dt, J = 1.6, 8.1 Hz, 1H, 
H-4'''), and 7.53 (dt, J = 0.9, 6.6 Hz, 1H, H-5'''). 
Similarly, the 4-methyl-1,3-thiazole moiety  was 
deduced through two peaks at δ 6.80 (br.s, 1H,  
 
 
Figure 2: 1H-NMR spectrum of 8e 
 
H-5) and 2.27 (s, 3H, CH3-6) while the 
interconnecting C & N-substituted acetamido 
moiety  in the molecule was inferred by two 
characteristic peaks at δ 12.47 (s, 1H, CON-H), 
and 4.40 (br.s, 2H, CH2-2'). In 13C-NMR 
spectrum (Figure 3), overall, fourteen signals 
clearly indicated the successful synthesis of the 
desired compound. The spectrum  identified 
seven quaternary carbons at δ 165.01 (C-1'), 
163.39 (C-5''), 163.30 (C-2''), 156.66 (C-2), 
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146.87 (C-4), 131.66 (C-2'''), & 122.06 (C-1'''), 
five methines at δ 133.30 (C-4'''), 131.10 (C-6'''), 
131.14 (C-3'''), 127.82 (C-5'''), & 108.12 (C-5), 
one methylene at δ 35.39 (C-2'), and a methyl 




Figure 3: 13C-NMR spectrum of 8e 
 
Various functional groups were ascribed to this 
molecule by IR data. The prominent absorption 
bands were observed at δ 3350 (N-H stretching), 
2973 (C-H stretching of aromatic ring), 1670 
(C=N stretching), 1640 (C=O stretching), 1572 
(C=C stretching of aromatic ring), 1159 (C-O-C 
stretching) and 684 (C-Cl stretching) cm-1. This 
corroborated the structural confirmation of 8e as 
2-{[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl] 
sulfanyl}-N-(4-methyl-1,3-thiazol-2-yl)acetamide. 
A similar strategy was employed for the structural 
interpretation of the other compounds in the 
series. 
 
Enzyme inhibition, molecular docking and 
structure-activity relationship 
 
To ascertain the therapeutic potential of 8a-r, 
these compounds were tested for inhibitory 
activity against four pharmacologically relevant 
enzymes, namely, AChE, BChE, α-glucosidase 
and urease. The results are given as % inhibition 
and IC50 (50% inhibitory concentration) values in 
Table 2. The modes of interactions of the 
synthesized molecules (8a-r) with these 
enzymes were also described with in silico 
(molecular docking) study. All compounds except 
two, 8a and 8r, exhibited an inhibitory potential 
against AChE. The most promising compounds 
against this enzyme were 8l and 8q with IC50 
values of 17.25 ± 0.07 and 18.36 ± 0.08 µM, 
respectively, which might have been due to the 
presence of a substituted nitro group at the three 
position of the phenyl ring. 
 
Eserine was used as a positive control against 
this enzyme, having an IC50 of 0.04 ± 0.0001 µM. 
The better activity of 8l and 8q, relative to other 
derivatives in the series, might have been due to 
the presence of a 3-nitrophenyl group and benzyl 
group, respectively, in these molecules. 
 
Among the mono-chloro substituted analogues, 
8e-g, the order of activity was ortho > meta > 
para, as per their IC50 values: 8e (49.73 ± 0.15 
µM), 8f (53.15 ± 0.25 µM), and 8g (79.25 ± 0.05 
µM), respectively. It would be expected that the 
lower the IC50 value, the greater the inhibitory 
potential of any molecule will be. Dichloro-
substituted 8h (119.53±0.21µM), was less active 
than the mono-chloroderivatives. Similarly, in the 
case of amino-substituted analogues, the 
molecule with meta-amino group, 8i (72.85±0.24 
µM), was more active than that with a para-
amino group, 8j (92.74±0.15 µM). For the mono-
nitro regioisomers, 8k-m, the order of activity 
was meta > ortho > para as reflected by the IC50 
v for 8l (17.25±0.07 µM), 8k (29.53±0.12 µM), 
and 8m (36.84±0.08 µM), respectively.  In the di-
nitro substituted compounds, 8n-p, it was 
observed that substitution of an additional methyl 
group rendered the molecule more active relative 
to substitution with a chloro group. Among these 
derivatives, the order of activity was: 2-methyl-
3,5-dinitrophenyl>2-chloro-3,5-dinitrophenyl>3,5-
dinitrophenyl.This was obvious from their IC50 
values of 49.47±0.13 µM (8o), 59.47±0.25 µM 
(8p), and 63.80±0.45 µM (8n). 
 
Varying trends were observed in other 
derivatives of the series. All derivatives, 8a-r, 
were docked into the active pocket of this 
enzyme.  
 
All synthesized derivatives were computationally 
docked against α -glucosidase, AChE and BChE 
to explore the binding modes of the ligands. Four 
interactions were shown by the most active 
compound 8l in this series. Ser122 makes an 
acidic interaction with carbonyl oxygen of the 
ligand, with 8l giving a bond length of 3.46 Å. 
Trp84 gave the strongest backbone donor 
interaction with -HNof thiazol and two arene-
arene interactions with oxadiazol ring, having  
bond distances of  2.12, 3.75 and 3.93 Å , 
respectively, as identified from the 2D and 3D 
images of Figure 4.  
 
Against BChE, weak activity was shown by the 
synthesized compounds, and almost half of the 
synthesized compound were inactive, where a 
moderate inhibition potential was shown by the 
compound 8k, with an IC50 of 56.23±0.09 µM. 
This might have been attributed to the 
substitution of a 2-nitrophenyl group in the 
skeleton.  The docking results revealed  that the  
8k showed  three strong interactions, an acidic 
interaction between  Ser122 and acetyl moiety, a 
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backbone donor and an arene-arene interaction 
with Trp84, having bond lengths of 3.48, 2.07 
and 3.86 Å, respectively, as indicated in Figure 5 
(2D & 3D). 
 
 
Figure 4: The 2D (a) and 3D (b) interaction analysis of 
8l against AChE 
 
 
Figure 5: The 2D (a) and 3D (b) interaction analysis of 
8k against BChE 
 
Similarly, a very moderate inhibitory potential 
was demonstrated by most of the compounds 
against α-glucosidase. Acarbose was used as 
the reference standard (IC50 = 37.38 ± 0.12 μM). 
The molecule 8o (57.35 ± 0.17μM) exhibited 
relatively better inhibitory activity in the series 
studied against this enzyme. This improved 
activity might have been due to the incorporation 
of a 2-methyl-3,5-dinitrophenyl ring in the 
molecule.  
 
The 1,4 glycosidic linkage is hydrolyzed by α-
glucosidase. Postprandial hyperglycemia is 
caused by the inhibition of α-glucosidase [20]. 
Therefore, inhibition of α-glucosidase is 
considered important in managing type-2 
diabetes whose blood sugar is highest after 
eating complex carbohydrates. From the in silico 
study, (Figure 6) the hydrogen attached to 
nitrogen of the acetamoyl group in 8o was 
involved in strong polar bonding with Asp349 
giving a bond length of 2.12Å. In addition, 1,3,4-
oxadiazole and 4-methyl-1,3-thiazol-2-yl groups 
were also found to show arene-cation 




Figure 6: The 2D (a) and 3D (b) interaction analysis of 
8o against α-glucosidase. 
 
Some compounds were found to be active 
against urease but displayed feeble inhibition 
relative to the reference, thiourea (IC50 = 
21.11±0.12 μM). In comparison with the other 
synthesized derivatives, 8f possessed relatively 
considerable inhibitory activity, indicating that the 
incorporation of 3-chlorophenyl moiety was 
adequate for the inhibition of this enzyme. 
Against urease, the molecular docking study 
(Figure 7) of 8f revealed π-π and arene-cation 
interactions for the 4-methyl-1,3-thiazol-2-yl and 
3-chlorophenyl groups with His323 and His324, 
respectively. The hydrogen attached to nitrogen 
of the acetamoyl group was involved in polar 
bonding with Asp224, giving a bond length of 
2.16Å. 
 
The cytotoxicity of the synthesized compounds 
was evaluated by brine shrimp lethality. The 
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higher LD50 values of compounds 8d (498.7 
mM), 8l (466.7 mM) and 8h (395.4 mM) of brine 
shrimp lethality analysis demonstrated the lowest 
toxicity of these compounds. Thus the 
synthesized molecules might be used as new 
drug candidates for the related diseases shown 
by their enzyme inhibition behavior. 
 
 
Figure 7: The 2D (a) and 3D (b) interaction analysis of 




Most of the derivatives among the synthesized 
molecules displayed notable inhibitory activity 
against the selected enzymes, along with very 
low cytotoxicity. Therefore, these synthesized 
compounds may have important roles in drug 
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